Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Lilly CEO says businesses most affected by CVS move are small employers Stock reaction to CVS decision is 'overblown,' says investor Lilly tops Wall Street view for first quarter profit ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

The company also taking a hit after CVS announced a deal with Novo Nordisk, making Wegovy its preferred weight loss drug and dropping Eli Lilly's Mounjaro. Speaking of CVS, shares are rising after ...

and CVS (CVS) that could sideline Lilly's weight-loss drug Zepbound. Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to break down what's weighing on Eli Lilly's stock.